Neurosterix pulls in $105M for schizophrenia drug, taps Cobenfy vets

Neurosterix, which is reuniting some key figures behind Cobenfy, has corralled $105 million in a Series B to fund its lead schizophrenia candidate that hits one of the targets of Bristol Myers Squibb’s drug. The ...